Puesta al día en hipertensión pulmonar
Texto completo:
PDFResumen
En la práctica cardiológica en Cuba son frecuentemente referidos pacientes con sospecha clínica de hipertensión pulmonar, el mayor porcentaje de los casos para confirmación diagnóstica, definición de causas y abordaje terapéutico. El criterio para definirla es una presión media en la arteria pulmonar mayor de 25 mmHg. La enfermedad puede presentarse en distintos procesos clínicos, que se clasifican en 5 grupos. En este artículo se muestra una revisión de la bibliografía y las publicaciones más recientes acerca de este tema.
Referencias
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. DOI: https://doi.org/10.1093/eurheartj/ehv317
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J [Internet]. 2019 [citado 10 Ene 2021];53(1):1801913. Disponible en: https://doi.org/10.1183/13993003.01913-2018
Barberà JA, Román A, Gómez-Sánchez MA, Blanco I, Otero R, López-Reyes R, et al. Diagnóstico y tratamiento de la hipertensión pulmonar (Normativa SEPAR) [Internet]. Barcelona: Editorial Respira [citado 10 Ene 2021]; 2017. Disponible en: https://www.sogapar.info/wp-content/uploads/2016/12/7-Normativa-SEPAR-hipertension-pulmonar.pdf
Portillo K, Santos S, Madrigal I, Blanco I, Pare C, Borderias L, et al. Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol. 2010;46(3):129-34. DOI: https://doi.org/10.1016/j.arbres.2009.11.005
Pousada G, Baloira A, Vilariño C, Cifrian JM, Valverde D. Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS One [Internet]. 2014 [citado 12 Ene 2021];9(6):e100261. Disponible en: https://doi.org/10.1371/journal.pone.0100261
Montani D, Lau EM, Dorfmüller P, Girerd B, Jaïs X, Savale L, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-34. DOI: https://doi.org/10.1183/13993003.00026-2016
Tenorio J, Navas P, Barrios E, Fernández L, Nevado J, Quezada CA, et al. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet. 2015;88(6):579-83. DOI: https://doi.org/10.1111/cge.12549
Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. DOI: https://doi.org/10.1183/09031936.00092311
Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-33. DOI: https://doi.org/10.1016/j.healun.2012.06.002
Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2014;145(5):1064-70. DOI: https://doi.org/10.1378/chest.13-1510
Gómez-López EA. Hipertensión pulmonar asociada a enfermedad cardiaca izquierda. Enfoque diagnóstico y terapéutico. Rev Colomb Cardiol. 2017;24(Suppl 1):55-64. DOI: http://dx.doi.org/10.1016/j.rccar.2017.08.009
Barnett CF, Selby VM. Overview of WHO Group 2 pulmonary hypertension due to left heart disease. Advances in Pulmonary Hypertension. 2015;14(2):70-8. DOI: https://doi.org/10.21693/1933-088X-14.2.70
Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-16. DOI: https://doi.org/10.1016/j.jacc.2013.10.036
Barberà JA, Blanco I. Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. Curr Hypertens Rep. 2015;17(8):62. DOI: https://doi.org/10.1007/s11906-015-0574-9
López Guide MJ, Pérez de la Sota E, Forteza Gil A, Centeno Rodríguez J, Eixeres A, Velázquez MT, et al. Pulmonary thromboendarterectomy in 106 patients with chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2015;51(10):502-8. DOI: http://dx.doi.org/10.1016/j.arbres.2014.11.012
Coronel ML, Chamorro N, Blanco I, Amado V, Del Pozo R, Pomar JL, et al. Medical and surgical management for chronic thromboembolic pulmonary hypertension: a single center experience. Arch Bronconeumol. 2014;50(12):521-7. DOI: https://doi.org/10.1016/j.arbres.2014.04.011
Escribano-Subías P, Del Pozo R, Román-Broto A, Domingo Morera JA, Lara-Padrón A, Elías Hernández T, et al. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. Int J Cardiol. 2016;203:938-44. DOI: https://doi.org/10.1016/j.ijcard.2015.11.039
Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. DOI: https://doi.org/10.1056/nejmoa1209657
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5(10):785-94. DOI: https://doi.org/10.1016/s2213-2600(17)30305-3
Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25):2127-34. DOI: https://doi.org/10.1016/j.jacc.2008.08.059
Olsson KM, Wiedenroth CB, Kamp JC, Breithecker A, Fuge J, Krombach GA, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J [Internet]. 2017 [citado 15 Ene 2021];49(6):1602409. Disponible en: https://doi.org/10.1183/13993003.02409-2016
Velázquez Martín M, Albarrán González-Trevilla A, Alonso Charterina S, García Tejada J, Cortina Romero JM, Escribano Subías P. Angioplastia pulmonar con balón en la hipertensión pulmonar tromboembólica crónica no operable. Experiencia inicial en España en una serie de 7 pacientes. Rev Esp Cardiol. 2015;68(6):535-7. DOI: https://doi.org/10.1016/j.rec.2015.02.004
Phan K, Jo HE, Xu J, Lau EM. Medical Therapy Versus Balloon Angioplasty for CTEPH: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018;27(1):89-98. DOI: https://doi.org/10.1016/j.hlc.2017.01.016
Barberà JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Estándares asistenciales en hipertensión pulmonar: Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC). Arch Bronconeumol. 2008;44(2):87-99. DOI: https://doi.org/10.1157/13115748
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. DOI: https://doi.org/10.1056/nejm199207093270203
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. DOI: https://doi.org/10.1016/j.jacc.2010.01.027
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. DOI: https://doi.org/10.1056/nejmoa1503184
Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011;38(6):1343-8. DOI: https://doi.org/10.1183/09031936.00072210
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(9):834-44. DOI: https://doi.org/10.1056/nejmoa1413687
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301. DOI: https://doi.org/10.1056/nejm199602013340504
Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-7. DOI: https://doi.org/10.1183/09031936.00116313
Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S-62S. DOI: https://doi.org/10.1378/chest.126.1_suppl.35s
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. DOI: https://doi.org/10.1016/s0735-1097(02)02012-0
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(12):1025-30. DOI: https://doi.org/10.1136/thx.2005.040618
Wensel R, Opitz CF, Anker SD, Winkler J, Höffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. DOI: https://doi.org/10.1161/01.cir.0000022687.18568.2a
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4):429-35. DOI: https://doi.org/10.1161/hc2901.093198
Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-70. DOI: https://doi.org/10.1161/01.cir.102.8.865
Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313-21. DOI: https://doi.org/10.1378/chest.129.5.1313
Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-9. DOI: https://doi.org/10.1016/s0735-1097(02)01744-8
Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-41. DOI: https://doi.org/10.1164/rccm.200604-547oc
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25(2):244-9. DOI: https://doi.org/10.1183/09031936.05.00054804
Enlaces refback
- No hay ningún enlace refback.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
